{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:53:22Z","timestamp":1790351602271,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.amjms.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:51:26Z","timestamp":1763761886000},"page":"255-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world evaluation of Evusheld in prevention of COVID-19 in immunocompromised patients: An observational cohort study"],"prefix":"10.1016","volume":"371","author":[{"given":"Sarah","family":"Channey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramodini","family":"Kale-Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lebovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2025.11.007_bib0001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/v15010118","article-title":"Tixagevimab\/Cilgavimab in SARS-CoV-2 prophylaxis and therapy: a comprehensive review of clinical experience","volume":"15","author":"Akinosoglou","year":"2022","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.amjms.2025.11.007_bib0002","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40265-022-01731-1","article-title":"Tixagevimab + Cilgavimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.amjms.2025.11.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00333-23","article-title":"Molecular characterization of AZD7442 (Tixagevimab-Cilgavimab) neutralization of SARS-CoV-2 omicron subvariants","volume":"11","author":"Roe","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"12","key":"10.1016\/j.amjms.2025.11.007_bib0004","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.amjms.2025.11.007_bib0005","doi-asserted-by":"crossref","first-page":"1654.e1","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.amjms.2025.11.007_bib0006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjms.2025.11.007_bib0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjms.2025.11.007_bib0008","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.amjms.2025.11.007_bib0009","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2025.11.007_bib0010","doi-asserted-by":"crossref","unstructured":"WolfeCR, CohenJ, MahoneyK, et al. Safety and efficacy of Pemivibart, a long-acting monoclonal antibody, for prevention of symptomatic COVID-19: interim results from the CANOPY clinical trial. medRxiv. https:\/\/doi.org\/10.1101\/2024.11.11.24317127.","DOI":"10.1101\/2024.11.11.24317127"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925012741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:08:54Z","timestamp":1772100534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925012741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0002962925012741"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.11.007","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world evaluation of Evusheld in prevention of COVID-19 in immunocompromised patients: An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}